Comparison of gene expression profiles altered by comfrey and riddelliine in rat liver
详细信息 查看全文
- 作者：Lei Guo (1)
Nan Mei (2)
Stacey Dial (1)
James Fuscoe (1)
Tao Chen (2) - 刊名：BMC Bioinformatics
- 出版年：2007
- 出版时间：November 2007
- 年：2007
- 卷：8
- 期：7-supp
- 全文大小：1912KB
- 参考文献：1. Rode D: Comfrey toxicity revisited. / Trends Pharmacol Sci 2002,23(11):497鈥?99. CrossRef
2. Yeong ML, Swinburn B, Kennedy M, Nicholson G: Hepatic veno-occlusive disease associated with comfrey ingestion. / J Gastroenterol Hepatol 1990,5(2):211鈥?14. CrossRef
3. Weston CF, Cooper BT, Davies JD, Levine DF: Veno-occlusive disease of the liver secondary to ingestion of comfrey. / Br Med J (Clin Res Ed) 1987,295(6591):183. CrossRef
4. Ridker PM, Ohkuma S, McDermott WV, Trey C, Huxtable RJ: Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. / Gastroenterology 1985,88(4):1050鈥?054.
5. Hirono I, Mori H, Haga M: Carcinogenic activity of Symphytum officinale. / J Natl Cancer Inst 1978,61(3):865鈥?69.
6. USFDA: Center for Food Safety and Applied Nutrition: FDA advises dietary supplement manufacturers to remove comfrey products from the market. [http://vmcfsanfdagov/~dms/dspltr06html] / FDA 2001.
7. Kim NC, Oberlies NH, Brine DR, Handy RW, Wani MC, Wall ME: Isolation of symlandine from the roots of common comfrey ( Symphytum officinale ) using countercurrent chromatography. / J Nat Prod 2001,64(2):251鈥?53. CrossRef
8. Schaneberg BT, Molyneux RJ, Khan IA: Evaporative light scattering detection of pyrrolizidine alkaloids. / Phytochem Anal 2004,15(1):36鈥?9. CrossRef
9. Stickel F, Seitz HK: The efficacy and safety of comfrey. / Public Health Nutr 2000,3(4A):501鈥?08. CrossRef
10. Fu PP, Xia Q, Lin G, Chou MW: Pyrrolizidine alkaloids 鈥?genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. / Drug Metab Rev 2004,36(1):1鈥?5. CrossRef
11. Prakash AS, Pereira TN, Reilly PE, Seawright AA: Pyrrolizidine alkaloids in human diet. / Mutat Res 1999,443(1鈥?):53鈥?7.
12. Mei N, Guo L, Fu PP, Heflich RH, Chen T: Mutagenicity of comfrey ( Symphytum Officinale ) in rat liver. / Br J Cancer 2005,92(5):873鈥?75. CrossRef
13. Hennings H, Glick AB, Greenhalgh DA, Morgan DL, Strickland JE, Tennenbaum T, Yuspa SH: Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. / Proc Soc Exp Biol Med 1993,202(1):1鈥?.
14. Knudson AG: Antioncogenes and human cancer. / Proc Natl Acad Sci USA 1993,90(23):10914鈥?0921. CrossRef
15. Moolgavkar SH, Knudson AG Jr: Mutation and cancer: a model for human carcinogenesis. / J Natl Cancer Inst 1981,66(6):1037鈥?052.
16. Loeb LA: A mutator phenotype in cancer. / Cancer Res 2001,61(8):3230鈥?239.
17. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, / et al.: Patterns of somatic mutation in human cancer genomes. / Nature 2007,446(7132):153鈥?58. CrossRef
18. Chan PC, Haseman JK, Prejean JD, Nyska A: Toxicity and carcinogenicity of riddelliine in rats and mice. / Toxicol Lett 2003,144(3):295鈥?11. CrossRef
19. Chan PC, Mahler J, Bucher JR, Travlos GS, Reid JB: Toxicity and carcinogenicity of riddelliine following 13 weeks of treatment to rats and mice. / Toxicon 1994,32(8):891鈥?08. CrossRef
20. National Toxicology Program: Toxicology and carcinogenesis studies of riddelliine (CAS No. 23246鈥?6鈥?) in F344/N rats and B6C3F1 mice (gavage studies). / Natl Toxicol Program Tech Rep Ser 2003, (508):1鈥?80.
21. Yang Y, Yan J, Churchwell M, Beger R, Chan P, Doerge DR, Fu PP, Chou MW: Development of a (32)P-postlabeling/HPLC method for detection of dehydroretronecine-derived DNA adducts in vivo and in vitro. / Chem Res Toxicol 2001,14(1):91鈥?00. CrossRef
22. Yang YC, Yan J, Doerge DR, Chan PC, Fu PP, Chou MW: Metabolic activation of the tumorigenic pyrrolizidine alkaloid, riddelliine, leading to DNA adduct formation in vivo. / Chem Res Toxicol 2001,14(1):101鈥?09. CrossRef
23. Chou MW, Jian Y, Williams LD, Xia Q, Churchwell M, Doerge DR, Fu PP: Identification of DNA adducts derived from riddelliine, a carcinogenic pyrrolizidine alkaloid. / Chem Res Toxicol 2003,16(9):1130鈥?137. CrossRef
24. Chou MW, Wang YP, Yan J, Yang YC, Beger RD, Williams LD, Doerge DR, Fu PP: Riddelliine N-oxide is a phytochemical and mammalian metabolite with genotoxic activity that is comparable to the parent pyrrolizidine alkaloid riddelliine. / Toxicol Lett 2003,145(3):239鈥?47. CrossRef
25. Chou MW, Yan J, Nichols J, Xia Q, Beland FA, Chan PC, Fu PP: Correlation of DNA adduct formation and riddelliine-induced liver tumorigenesis in F344 rats and B6C3F(1) mice. / Cancer Lett 2003,193(2):119鈥?25. CrossRef
26. Mei N, Heflich RH, Chou MW, Chen T: Mutations induced by the carcinogenic pyrrolizidine alkaloid riddelliine in the liver cII gene of transgenic Big Blue rats. / Chem Res Toxicol 2004,17(6):814鈥?18. CrossRef
27. Mei N, Chou MW, Fu PP, Heflich RH, Chen T: Differential mutagenicity of riddelliine in liver endothelial and parenchymal cells of transgenic Big Blue rats. / Cancer Lett 2004,215(2):151鈥?58. CrossRef
28. Lettieri T: Recent applications of DNA microarray technology to toxicology and ecotoxicology. / Environ Health Perspect 2006,114(1):4鈥?.
29. Liu-Stratton Y, Roy S, Sen CK: DNA microarray technology in nutraceutical and food safety. / Toxicol Lett 2004,150(1):29鈥?2. CrossRef
30. Boorman GA, Blackshear PE, Parker JS, Lobenhofer EK, Malarkey DE, Vallant MK, Gerken DK, Irwin RD: Hepatic gene expression changes throughout the day in the Fischer rat: implications for toxicogenomic experiments. / Toxicol Sci 2005,86(1):185鈥?93. CrossRef
31. Desai VG, Moland CL, Branham WS, Delongchamp RR, Fang H, Duffy PH, Peterson CA, Beggs ML, Fuscoe JC: Changes in expression level of genes as a function of time of day in the liver of rats. / Mutat Res 2004,549(1鈥?):115鈥?29.
32. Mei N, Guo L, Zhang L, Shi L, Sun YA, Fung C, Moland CL, Dial SL, Fuscoe JC, Chen T: Analysis of gene expression changes in relation to toxicity and tumorigenesis in the livers of Big Blue transgenic rats fed comfrey ( Symphytum officinale ). / BMC Bioinformatics 2006,7(Suppl 2):S16. CrossRef
33. Mei N, Guo L, Liu R, Fuscoe JC, Chen T: Gene expression changes induced by the tumorigenic pyrrolizidine alkaloid riddelliine in liver of Big Blue rats. / BMC Bioinformatics 2007, / in press.
34. Williams DE, Reed RL, Kedzierski B, Ziegler DM, Buhler DR: The role of flavin-containing monooxygenase in the N-oxidation of the pyrrolizidine alkaloid senecionine. / Drug Metab Dispos 1989,17(4):380鈥?86.
35. Lame MW, Morin D, Jones AD, Segall HJ, Wilson DW: Isolation and identification of a pyrrolic glutathione conjugate metabolite of the pyrrolizidine alkaloid monocrotaline. / Toxicol Lett 1990,51(3):321鈥?29. CrossRef
36. Lin G, Cui YY, Hawes EM: Microsomal formation of a pyrrolic alcohol glutathione conjugate of clivorine. Firm evidence for the formation of a pyrrolic metabolite of an otonecine-type pyrrolizidine alkaloid. / Drug Metab Dispos 1998,26(2):181鈥?84.
37. Yan CC, Huxtable RJ: Effects of monocrotaline, a pyrrolizidine alkaloid, on glutathione metabolism in the rat. / Biochem Pharmacol 1996,51(3):375鈥?79. CrossRef
38. Yu J, Baron V, Mercola D, Mustelin T, Adamson ED: A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. / Cell Death Differ 2007,14(3):436鈥?46. CrossRef
39. Mosser DD, Caron AW, Bourget L, Denis-Larose C, Massie B: Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. / Mol Cell Biol 1997,17(9):5317鈥?327.
40. Dennis JW, Granovsky M, Warren CE: Glycoprotein glycosylation and cancer progression. / Biochim Biophys Acta 1999,1473(1):21鈥?4.
41. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW: Suppression of tumor growth and metastasis in Mgat5-deficient mice. / Nat Med 2000,6(3):306鈥?12. CrossRef
42. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM: The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. / Proc Natl Acad Sci USA 1999,96(7):3928鈥?933. CrossRef
43. Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM: FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. / Proc Natl Acad Sci USA 2001,98(18):10374鈥?0379. CrossRef
44. Tong W, Cao X, Harris S, Sun H, Fang H, Fuscoe J, Harris A, Hong H, Xie Q, Perkins R, / et al.: ArrayTrack 鈥?supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. / Environ Health Perspect 2003,111(15):1819鈥?826. - 作者单位：Lei Guo (1)
Nan Mei (2)
Stacey Dial (1)
James Fuscoe (1)
Tao Chen (2)
1. Division of Systems Toxicology, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA
2. Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, FDA, Jefferson, AR, 72079, USA - ISSN：1471-2105
文摘
Background Comfrey (Symphytum officinale) is a perennial plant and has been consumed by humans as a vegetable, a tea and an herbal medicine for more than 2000 years. It, however, is hepatotoxic and carcinogenic in experimental animals and hepatotoxic in humans. Pyrrolizidine alkaloids (PAs) exist in many plants and many of them cause liver toxicity and/or cancer in humans and experimental animals. In our previous study, we found that the mutagenicity of comfrey was associated with the PAs contained in the plant. Therefore, we suggest that carcinogenicity of comfrey result from those PAs. To confirm our hypothesis, we compared the expression of genes and processes of biological functions that were altered by comfrey (mixture of the plant with PAs) and riddelliine (a prototype of carcinogenic PA) in rat liver for carcinogenesis in this study. Results Groups of 6 Big Blue Fisher 344 rats were treated with riddelliine at 1 mg/kg body weight by gavage five times a week for 12 weeks or fed a diet containing 8% comfrey root for 12 weeks. Animals were sacrificed one day after the last treatment and the livers were isolated for gene expression analysis. The gene expressions were investigated using Applied Biosystems Rat Whole Genome Survey Microarrays and the biological functions were analyzed with Ingenuity Analysis Pathway software. Although there were large differences between the significant genes and between the biological processes that were altered by comfrey and riddelliine, there were a number of common genes and function processes that were related to carcinogenesis. There was a strong correlation between the two treatments for fold-change alterations in expression of drug metabolizing and cancer-related genes. Conclusion Our results suggest that the carcinogenesis-related gene expression patterns resulting from the treatments of comfrey and riddelliine are very similar, and PAs contained in comfrey are the main active components responsible for carcinogenicity of the plant.